wherein A^1 to A^3 and R^1 to R^3 are as defined above, X is a leaving group and M is a suitably substituted metalspecies.

~~In another aspect, there is provided a compound as defined herein, when manufactured according to a process as defined herein.~~

In another aspect, there is provided a compound as defined herein for use as therapeutically active substance.


In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein and a therapeutically inert carrier.

In another aspect, there is provided use of a compound as defined herein in the manufacture of a medicament for the treatment or prophylaxis of pain, atherosclerosis, ~~age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus,~~ inflammation, ~~inflammatory bowel disease,~~ ischemia-reperfusion injury, ~~acute liver failure,~~ liver fibrosis, ~~lung fibrosis, kidney fibrosis,~~ systemic fibrosis, ~~acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia,~~ myocardial infarction, ~~systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors,~~ regulation of bone mass~~, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease,~~ or stroke~~, transient ischemic attack or uveitis~~.

In another aspect, there is provided a compound as defined herein for use in the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis.

In the present description the term "alkyl", alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, particularly a straight or branched-chain alkyl group with 1 to 6 carbon atoms and more particularly a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straight-

(d) the reaction of a compound of formula (D)



(D)

in the presence of MR^1, a palladium catalyst and a base;

wherein A^1 to A^3 and R^1 to R^3 are as defined in any one of claims 1 to 13, X is a leaving group and M is a suitably substituted metalspecies.

~~15. A compound according to any one of claims 1 to 13, when manufactured according to a process of claim 14.~~

~~16~~15. A compound according to any one of claims 1 to 13 for use as therapeutically active substance.

~~17~~16. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 13 and a therapeutically inert carrier.

~~18~~17. The use of a compound according to any one of claims 1 to 13 in the manufacture of a medicament for the treatment or prophylaxis of pain, atherosclerosis, ~~age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes~~

~~mellitus,~~ inflammation, ~~inflammatory bowel disease,~~ ischemia-reperfusion injury, ~~acute liver failure,~~ liver fibrosis, ~~lung fibrosis, kidney fibrosis,~~ systemic fibrosis, ~~acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia,~~ myocardial infarction, ~~systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors,~~ regulation of bone mass, ~~amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease,~~ or stroke~~, transient ischemic attack or uveitis~~.

~~19~~18. A compound according to any one of claims 1 to 13 for use in the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis.

***